Inovio Pharmaceuticals Inc (NASDAQ:INO) has received an average rating of “Buy” from the eight research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $6.82.
A number of research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Inovio Pharmaceuticals in a report on Wednesday, November 13th. Maxim Group restated a “buy” rating on shares of Inovio Pharmaceuticals in a report on Thursday, November 14th. Finally, Citigroup restated a “buy” rating and set a $4.00 price target (down previously from $7.00) on shares of Inovio Pharmaceuticals in a report on Monday, September 16th.
A number of institutional investors and hedge funds have recently made changes to their positions in INO. Creative Planning bought a new position in Inovio Pharmaceuticals in the 2nd quarter worth $50,000. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Inovio Pharmaceuticals by 53.1% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,884,100 shares of the biopharmaceutical company’s stock worth $14,359,000 after buying an additional 1,694,891 shares during the period. Stoneridge Investment Partners LLC bought a new position in Inovio Pharmaceuticals during the 2nd quarter worth approximately $50,000. Nikko Asset Management Americas Inc. raised its holdings in Inovio Pharmaceuticals by 49.7% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 4,884,100 shares of the biopharmaceutical company’s stock worth $14,359,000 after purchasing an additional 1,621,581 shares during the last quarter. Finally, ARK Investment Management LLC raised its holdings in Inovio Pharmaceuticals by 35.0% during the 2nd quarter. ARK Investment Management LLC now owns 3,955,017 shares of the biopharmaceutical company’s stock worth $11,628,000 after purchasing an additional 1,025,420 shares during the last quarter. Hedge funds and other institutional investors own 46.38% of the company’s stock.
Shares of Inovio Pharmaceuticals stock traded up $0.05 during midday trading on Monday, reaching $2.39. 1,057,520 shares of the company’s stock traded hands, compared to its average volume of 965,577. The company has a market cap of $238.52 million, a price-to-earnings ratio of -2.27 and a beta of 2.14. The company’s 50 day simple moving average is $2.40 and its 200 day simple moving average is $2.51. The company has a debt-to-equity ratio of 2.52, a quick ratio of 5.06 and a current ratio of 5.06. Inovio Pharmaceuticals has a 52 week low of $1.91 and a 52 week high of $5.38.
Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The business had revenue of $0.87 million for the quarter, compared to the consensus estimate of $2.72 million. Inovio Pharmaceuticals had a negative net margin of 1,809.64% and a negative return on equity of 179.91%. During the same quarter last year, the firm earned ($0.27) EPS. As a group, equities research analysts predict that Inovio Pharmaceuticals will post -1.08 earnings per share for the current year.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.